Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling
about
Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012Psychiatric aspects of phosphodiesterases: An overview.Grape powder intake prevents ovariectomy-induced anxiety-like behavior, memory impairment and high blood pressure in female Wistar ratsHow cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders: a critical review of biological pathways.Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanismscGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress.The distribution of phosphodiesterase 2A in the rat brain.cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.Prenatal and Early Postnatal Exposure to Cigarette Smoke Decreases BDNF/TrkB Signaling and Increases Abnormal Behaviors Later in LifeNovel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment.Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.The impact of dosing interval in a novel tandem oral dosing strategy: enhancing the exposure of low solubility drug candidates in a preclinical setting.Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders.PDE Inhibitors for the Treatment of Schizophrenia.The phosphodiesterase type 2 inhibitor BAY 60-7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity.Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.Uncovering the Signaling Pathway behind Extracellular Guanine-Induced Activation of NO System: New Perspectives in Memory-Related Disorders.In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.Purin-6-One Derivatives as Phosphodiesterase-2 Inhibitors
P2860
Q26746978-041DD732-53E9-4E81-ABD1-BC59DA259514Q28078128-407921B6-22F9-471E-A1B5-1E20EEAE3702Q28536947-0A9730DD-5D84-4F1F-A75C-B4C5EB7B2FEAQ30453328-2D87C173-8ED7-4D98-834D-AD6C5564C111Q33821243-8382F301-5BFC-4442-B24C-7BC888B8FAA4Q34244951-46E49112-ACEA-4975-BB2F-66E653B6A589Q35047703-6EE2411D-04AA-4599-AA77-FEE220EEB3B4Q35538783-EA88F57B-09C4-45E5-9D8F-1011B4F30EE4Q35687052-F27524C0-C31E-4243-9F9B-375981F9B51AQ36950565-204FFD0A-F02D-4604-9886-8897EDAF87F5Q37661357-A35FC558-DE52-410E-9C08-B2A86CAC4A1AQ37947681-27CBA694-242D-4A87-ABDF-2D6F9483DEC7Q38870312-120337C2-53BC-49CE-A0BB-B64C9FF8B9FCQ39817182-0156B3E0-972B-45E8-80BA-3A88020F0AFEQ40190681-D50947C6-6E9B-4488-AD35-84369823DFC4Q41435708-CF3D1786-A915-4506-AE86-D17B868F5292Q42704990-4F1048F6-229A-4A7F-8A84-EA8AB0A9218BQ45021536-971A83EB-22A3-45FE-BA7A-B1167C9C2275Q45068634-B77C9AF1-DC73-4C77-94FB-47026F1A43CEQ47611419-DBD788A3-B5EE-4382-B348-6A54DB63E244Q47887284-8B9D71DD-1186-47B0-9D42-5115B37A89F9Q48157920-3F175A89-BE58-4BCA-B531-0E4966AFD0C0Q50420451-AF319BF0-1251-4AB9-8769-86F8B6274734Q50684220-657CFA9F-6C13-41C9-9C59-F34C71A9B0DEQ59125665-B5E0C4CF-8F76-4FDA-943F-5CA5E4A1446B
P2860
Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anxiolytic effects of phosphod ...... with increased cGMP signaling
@en
Anxiolytic effects of phosphod ...... with increased cGMP signaling.
@nl
type
label
Anxiolytic effects of phosphod ...... with increased cGMP signaling
@en
Anxiolytic effects of phosphod ...... with increased cGMP signaling.
@nl
prefLabel
Anxiolytic effects of phosphod ...... with increased cGMP signaling
@en
Anxiolytic effects of phosphod ...... with increased cGMP signaling.
@nl
P2093
P2860
P356
P1476
Anxiolytic effects of phosphod ...... with increased cGMP signaling
@en
P2093
Adel Hamza
Anbrin Masood
Chang-Guo Zhan
Hassan Hajjhussein
Ying Huang
P2860
P304
P356
10.1124/JPET.109.156729
P407
P577
2009-08-14T00:00:00Z